SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001521536-12-001019
Filing Date
2012-10-17
Accepted
2012-10-17 11:26:25
Documents
2

Document Format Files

Seq Description Document Type Size
1 q1100788_nabi13d-xstelos.htm SC 13D 63893
2 LETTER FROM XSTELOS HOLDINGS, INC. TO NABI BIOPHARMACEUTICALS DATED OCTOBER 16, q1100788_ex99-1.htm EX-99.1 9100
  Complete submission text file 0001521536-12-001019.txt   74819
Mailing Address 12270 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Subject) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-31596 | Film No.: 121147590
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 630 FIFTH AVENUE SUITE 2260 NEW YORK NY 10020
Business Address 630 FIFTH AVENUE SUITE 2600 NEW YORK NY 10020 201-934-2000
Xstelos Holdings, Inc. (Filed by) CIK: 0001540145 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations